Holdings
Frazier Life Sciences Management, L.P.
As of Sep 30, 2026, Frazier Life Sciences Management, L.P. reported 41 positions worth US$3.51B. Largest: Mirum Pharmaceuticals, Inc., Erasca, Inc. and MBX Biosciences, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc. | 7.68M | US$656M | no change | Sep 30, 2026 |
| Erasca, Inc. | 29.5M | US$432M | +4.5M | Sep 30, 2026 |
| MBX Biosciences, Inc. | 6.65M | US$390M | no change | Sep 30, 2026 |
| Arcutis Biotherapeutics, Inc. | 9.87M | US$261M | no change | Sep 30, 2026 |
| Maze Therapeutics, Inc. | 5.28M | US$144M | +250K | Sep 30, 2026 |
| Trevi Therapeutics, Inc. | 9.54M | US$137M | −400K | Sep 30, 2026 |
| Krystal Biotech, Inc. | 391K | US$130M | −89,988 | Sep 30, 2026 |
| Palvella Therapeutics, Inc. | 882K | US$122M | no change | Sep 30, 2026 |
| Attovia Therapeutics, Inc. | 7.05M | US$121M | new | Sep 30, 2026 |
| Braveheart Bio, Inc. | 5.27M | US$106M | new | Sep 30, 2026 |